



Global Conference of Parliamentarians on

Population and Development


Toward the 2023 G7 Hiroshima Summit (GCPPD2023)

Ageing Population and Healthy Longevity

Dr. Leon Ochiai, Head of Public Affairs, Sanofi Japan


April 25th, 2023

Protecting the health of older adult is crucial for the society and the economy




- In Japan, people aged 50 and over already accounted for more than 2 in 5 workers (40% of the workforce) in 2017 – this could rise to 47% by 2035.
- More than 3 in 5 Yen in the Japanese economy were spent by older households (those led by people aged 50 and older) in 2015; amounting to 21% of GDP.
- The value of unpaid contributions by older people in Japan, such as volunteering and caring equate to 1% of GDP – just under a third of Japan's spending on education.

Infectious diseases, such as influenza can lead to severe complications impacting people's lives



And impacting on frailty in older people



Overview of the economic burden of influenza


Micro-economic costs
(measured at individual level)

Direct costs

Costs related to the disease itself:

- Over-the-counter drugs
- Lab tests and imaging
- General practitioner visits
- Emergency department visits
- Hospitalizations
 - medical wards
 - intensive care units

Indirect costs








Macro-economic costs
(measured at population level)



Healthcare system disruption

Total economic burden of influenza in industrialized countries

Geographic Area		Population size and age groups	Influenza seasons	Considered costs	Economic burden/year
	USA¹	316 million (overall population)	Average from prior seasons to 2015	Direct, indirect	11.2 billion USD
	European Union (EU-27)^{2,6}	495 million (overall population)	1997 and earlier	Direct, indirect	6-14 billion €
	Norway³	4.5 million (overall population)	1998-1999 to 2006-2007	Direct, indirect	253 million €
	Germany⁴	81 million (overall population)	2004-2005 to 2013-2014	Direct, indirect	0.3-3.1 billion €
	Korea⁵	40 millions (adults >20yo)	2013-2014	Direct, indirect	125 million USD

1. Putri et al. 2018, doi: [10.1016/j.vaccine.2018.05.057](https://doi.org/10.1016/j.vaccine.2018.05.057)

3. Xue Y et al. 2010, doi: [10.1186/1471-2458-10-724](https://doi.org/10.1186/1471-2458-10-724)

5. Choi et al. 2017, doi: [10.1371/journal.pone.0172012](https://doi.org/10.1371/journal.pone.0172012)

2. Preaud et al. 2014, doi: [10.1186/1471-2458-14-813](https://doi.org/10.1186/1471-2458-14-813)

4. Ehlken B et al. 2015, doi: [10.1186/s12889-015-1885-0](https://doi.org/10.1186/s12889-015-1885-0)

6. [Commission of the European Communities](http://ec.europa.eu/economy_finance/)

Immunization is A Critical Pillar of Healthy Ageing Policies



UN Decade of Healthy Ageing:

“Older people require non-discriminatory access to good-quality essential health services that include **prevention**; promotion; curative, rehabilitative, palliative and end-of-life care; safe, affordable, effective, good-quality essential medicines and **vaccines**; dental care and health and assistive technologies, while ensuring that use of these services does not cause the user financial hardship.



Immunization Agenda 2030:

A world where everyone, everywhere, at every age, fully benefits from vaccines for good health and well-being.

https://cdn.who.int/media/docs/default-source/decade-of-healthy-ageing/decade-proposal-final-apr2020-en.pdf?sfvrsn=b4b75ebc_28&download=true

<https://www.immunizationagenda2030.org/vision-and-impact>



sanofi

-

Protecting Public Health with Vaccines

Innovative immunization

Everyone deserves a chance to plan for the future. Our vaccines contribute to make it possible by preventing disease and reducing the severity of infections in people of all ages. We beat pathogens at their own game by studying their every move, zeroing in on their greatest vulnerabilities, and designing the best defense to neutralize the threat.

WHO ARE WE?

We are a Worldwide Leader in Human Vaccines



~15,500
employees worldwide

46% Female

54% Male

Source: Sanofi HR database – Workday prism, Feb 2022



We produce *a broad range of high-quality vaccines* to help protect people around the world from severe diseases at each and every stage of life.



We supply more than *2.5 million doses of vaccines every day*, making it possible to *immunize hundreds of millions of people* worldwide per year.



We invest more than **500 million euros in R&D** every year

Influenza



Worldwide, it's estimated that **3 to 5 million people have severe flu infections each year⁽¹⁾**, some of which can lead to unexpected, severe consequences such as heart attacks and strokes in addition to pneumonia and other life-threatening conditions.

HOW DO WE ACHIEVE OUR PURPOSE?

Partnering for Disease Prevention (some examples)

1 Access to Vaccines

- GPEI - Global Polio Eradication Initiative
- GAVI – the Vaccines Alliance
- EYE - Eliminate Yellow fever Epidemics
- EAASM – European Alliance for Access to Safe Medicines
- International organizations & NGOs: WHO, UNICEF, Rotary, Red Cross...

2 Life course immunization

- IFA - International Federation on Aging
- GCOA – Global Coalition on Aging
- WHF – World Heart Federation
- FIP – International Pharmaceutical Federation
- Sabin Institute

3 Disease surveillance

- Global Influenza Surveillance and Response System (GISRS)
- Global Influenza Hospital Surveillance Network (GIHSN)
- Centers for Disease Control and Prevention (CDC)
- European Centre for Disease Prevention and Control (ECDC)
- European Influenza surveillance network coordinated by ECDC (EISN)



R&D Partners 4

- BAIDU
- ACUITAS
- Institut Pasteur
- Public Health Institutes
- Universities

Pharma industry partners 5

- GSK
- AstraZeneca
- Merck
- SK Bioscience
- BioNTech
- Moderna
- Trade associations: IFPMA, EFPIA, BIO

Patient Association Groups 6

- European Patient Forum
- Meningitis Research Foundation
- European Foundation for the Care of Newborn Infants (EFCNI)